B&E Diagnostics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

B&E Diagnostics is a privately held, commercial-stage diagnostics company with a global footprint, founded in 1995 and headquartered in Boca Raton, USA, with significant operational and manufacturing presence in Yantai, China. The company has established itself as a volume manufacturer of mid-tier clinical laboratory analyzers and generic reagents, competing on value and breadth of portfolio in emerging and cost-conscious markets. Its strategy focuses on expanding its point-of-care (POC) offerings, such as handheld blood gas analyzers, and leveraging its extensive distributor network to drive international sales growth.

Diagnostics

Technology Platform

Applied engineering and manufacturing for a broad portfolio of established diagnostic modalities including automated hematology, ion-selective electrode (electrolytes), chromatography (HbA1c), and sensor-based cartridge POC (blood gas). Expertise in high-volume generic reagent manufacturing.

Opportunities

The global demand for cost-effective diagnostic solutions in emerging markets and cost-conscious labs provides a large, growing addressable market.

Expansion into handheld point-of-care devices, like the i-Check analyzer, allows entry into faster-growing, decentralized testing segments.

Recognition as a 'Little Giant' enterprise in China could facilitate growth within the strategically important domestic market.

Risk Factors

Intense competition from large multinational IVD corporations and other low-cost manufacturers creates constant pricing and margin pressure.

Geopolitical tensions and supply chain reliance on manufacturing in China pose significant operational and regulatory risks.

The business model requires continuous investment in R&D and regulatory compliance to avoid product obsolescence and maintain market access.

Competitive Landscape

B&E competes in the mid-to-low tier of the IVD market against large multinationals (e.g., Sysmex, Roche, Abbott, Siemens) and other value-focused manufacturers, particularly from China and India. In generic reagents, competition is based almost solely on price and regulatory status. For instruments, competition involves product features, reliability, cost-of-ownership, and the strength of distributor networks.

More companies in Diagnostics & Precision Medicine →More companies in United States →